Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/130309
Campo DC Valoridioma
dc.contributor.authorTrullàs, Joan Carles-
dc.contributor.authorMorales-Rull, José Luís-
dc.contributor.authorCasado, Jesús-
dc.contributor.authorCarrera-Izquierdo, Margarita-
dc.contributor.authorSánchez-Marteles, Marta-
dc.contributor.authorConde Martel, Alicia-
dc.contributor.authorDávila-Ramos, Melitón Francisco-
dc.contributor.authorLlácer, Pau-
dc.contributor.authorSalamanca-Bautista, Prado-
dc.contributor.authorChivite, David-
dc.contributor.authorJordana-Comajuncosa, Rosa-
dc.contributor.authorVillalonga, Maria-
dc.contributor.authorPáez-Rubio, María Inmaculada-
dc.contributor.authorManzano, Luís-
dc.contributor.authorFormiga, Francesc-
dc.date.accessioned2024-05-13T09:31:52Z-
dc.date.available2024-05-13T09:31:52Z-
dc.date.issued2023-
dc.identifier.issn1388-9842-
dc.identifier.urihttp://hdl.handle.net/10553/130309-
dc.description.abstractAims: In patients with acute heart failure (AHF), the addition of hydrochlorothiazide (HCTZ) to furosemide improved diuretic response in the CLOROTIC trial. This work aimed to evaluate if these effects differ across the estimated glomerular filtration rate (eGFR) spectrum. Methods and results: This post-hoc analysis of the CLOROTIC trial analysed 230 patients with AHF and explored the influence of eGFR on primary and secondary endpoints. The median eGFR was 43 ml/min/1.73 m2 (range 14–109) and 23% had eGFR ≥60 ml/min/1.73 m2 (group 1), 24% from 45 to 59 ml/min/1.73 m2 (group 2), and 53% <45 ml/min/1.73 m2 (group 3). Patients treated with HCTZ had greatest weight loss at 72 h in all three groups, but patients in group 1 had a significantly greater response (−2.1 kg [−3.0 to 0.5]), compared to patients in groups 2 (−1.3 kg [−2.3 to 0.2]) and 3 (−0.1 kg [−1.3 to 0.4]) (p-value for interaction = 0.246). At 96 h, the differences in weight were −1.8 kg (−3.0 to −0.3), −1.4 kg (−2.6 to 0.3), and −0.5 kg (−1.3 to −0.1) in groups 1, 2, and 3, respectively (p-value for interaction = 0.256). There were no significant differences observed with the addition of HCTZ in terms of diuretic response, mortality or rehospitalizations, or safety endpoints (impaired renal function, hyponatraemia, and hypokalaemia) among the three eGFR groups (all p-values for interaction were no significant). Conclusion: The addition of eGFR-adjusted doses of oral HCTZ to loop diuretics in patients with AHF improved diuretic response across the eGFR spectrum. Clinical Trial Registration: ClinicalTrials.gov: NCT01647932; EudraCT number: 2013–001852-36.-
dc.languageeng-
dc.relation.ispartofEuropean Journal of Heart Failure-
dc.sourceEuropean Journal of Heart Failure [1388-9842], v. 25, p. 1784–1793 (2023)-
dc.subject320501 Cardiología-
dc.subject.otherDiuretics-
dc.subject.otherFurosemide-
dc.subject.otherGlomerular filtration rate-
dc.subject.otherHeart failure-
dc.subject.otherThiazides-
dc.titleCombining loop and thiazide diuretics for acute heart failure across the estimated glomerular filtration rate spectrum: A post-hoc analysis of the CLOROTIC trial-
dc.typeinfo:eu-repo/semantics/article-
dc.typeArticle-
dc.identifier.doi10.1002/ejhf.2988-
dc.identifier.pmid37540036-
dc.identifier.scopus2-s2.0-85168145419-
dc.contributor.orcid0000-0002-7380-3475-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.description.lastpage1793-
dc.identifier.issue10-
dc.description.firstpage1784-
dc.relation.volume25-
dc.investigacionCiencias de la Salud-
dc.type2Artículo-
dc.description.numberofpages10-
dc.utils.revision-
dc.date.coverdateAgosto 2016-
dc.identifier.ulpgcNo-
dc.identifier.ulpgc-
dc.contributor.buulpgcBU-MED-
dc.description.sjr5,919-
dc.description.jcr16,9-
dc.description.sjrqQ1-
dc.description.jcrqQ1-
dc.description.scieSCIE-
dc.description.miaricds10,8-
item.fulltextCon texto completo-
item.grantfulltextopen-
crisitem.author.deptGIR IUIBS: Patología y Tecnología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-2540-3880-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameConde Martel, Alicia-
Colección:Artículos
Unknown (1,01 MB)
Vista resumida

Citas SCOPUSTM   

16
actualizado el 30-mar-2025

Citas de WEB OF SCIENCETM
Citations

15
actualizado el 30-mar-2025

Visitas

57
actualizado el 01-nov-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.